This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bruker (BRKR) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex xMAP Picked by EDP Biotech to Boost Cancer Diagnostics
by Zacks Equity Research
Management at Luminex (LMNX) expects to see robust demand for Luminex's xMAP technology in 2019.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.
Medtronic Receives FDA Nod for SelectSite Catheter System
by Zacks Equity Research
The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.
Masimo's Technologies to be Deployed to Boost Pediatric Care
by Zacks Equity Research
NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
by Zacks Equity Research
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
Here's Why You Should Retain NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investor confidence in the stock is high on Hill-Rom's (HRC) recent acquisition of Voalte.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) raises revenue guidance for 2019 encourages.
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
Here's Why Momentum Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bruker (BRKR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Looking for a Growth Stock? 3 Reasons Why Bruker (BRKR) is a Solid Choice
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 16.67% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scientific Instruments Industry Outlook: Prospects Look Bright
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is benefiting from solid prospects in emerging markets, robust end-market demand and increasing spending on health care.
Top Ranked Growth Stocks to Buy for April 11th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 11th.
Top Ranked Growth Stocks to Buy for April 10th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, April 10th.
Top Ranked Growth Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 8th.
Are You Looking for a Top Momentum Pick? Why Bruker (BRKR) is a Great Choice
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Growth Stocks to Buy for March 29th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 29th.
Is Bruker (BRKR) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker Consistently Gains From NANO & New Strategic Buyouts
by Zacks Equity Research
Bruker (BRKR) is progressing well with its three strategic buyouts, indicative of a majority interest in both Hain Diagnostics and Mestrelab along with the Alicona Imaging acquisition.
Top Ranked Growth Stocks to Buy for March 27th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, March 27th.